University of Rochester Medical Center Wilmot Cancer Center
Strong Memorial Hospital
Rochester, NY
Accepting patients
MonumenTAL-1
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- GPRC5D
- Phase 2
Not yet accepting
ROTATE
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) (ROTATE)
- Bispecific Antibody
- GPRC5D
- BCMA
- Minimal Residual Disease (MRD)
- Post-Autologous Stem Cell Transplant
- Phase 2
Accepting patients
OPN-662
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
- BET Inhibitor
- Phase 1
- Has results
Accepting patients
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Monoclonal Antibody
- CD38
- Randomization
- Maintenance
- Phase 3
Accepting patients
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Monoclonal Antibody
- CD38
- Phase 3
Accepting patients
QXL138AM
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Masked Immunocytokine (MIC)
- CD138
- Phase 1
2 hidden based on your filters.Show All